Bydureon 2 mg powder and solvent for prolonged-release suspension for injection in pre-filled pen * Pharmacy Only: Prescription
Company:
AstraZeneca Pharmaceuticals (Ireland) DACStatus:
UpdatedLegal Category:
Product subject to medical prescription which may not be renewed (A)Active Ingredient(s):
*Additional information is available within the SPC or upon request to the company
What is a Patient Information Leaflet and why is it useful?
A Patient Information Leaflet (PIL) is the leaflet for patients containing information on taking a medicine, that is included with the medicine packaging. It is written by pharmaceutical companies as a patient version of the Summary of Product Characteristics (SPC). Changes to the PIL after your medicine was packed may mean that the version on medicines.ie may differ from the version found with your medicine. You can compare the “Leaflet prepared or revised date” towards the end of the leaflet in the pack with the version that is on the website to find out if there have been any changes to the information since your medicine was packed.
20220714 Package Leaflet IE MT Bydureon DCP CDS Update (gallbladder) CV 22 0019
Last updated: 18/07/22
Product Notice
Discontinued Strength Notice
Bydureon 2 mg Powder and Solvent for Prolonged-Release Suspension for Injection in Pre-Filled Pen has been discontinued. It is expected that stock will be depleted by September 2022.